Medigene AG Price Prediction

MDGEFDelisted Stock  USD 2.59  0.00  0.00%   
As of 29th of November 2024 the relative strength index (rsi) of Medigene's share price is below 20 . This indicates that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.

Oversold Vs Overbought

0

 
Oversold
 
Overbought
The successful prediction of Medigene's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Medigene and does not consider all of the tangible or intangible factors available from Medigene's fundamental data. We analyze noise-free headlines and recent hype associated with Medigene AG, which may create opportunities for some arbitrage if properly timed.
Using Medigene hype-based prediction, you can estimate the value of Medigene AG from the perspective of Medigene response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Medigene to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Medigene because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Medigene after-hype prediction price

    
  USD 2.59  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Medigene's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
1.881.882.85
Details
Naive
Forecast
LowNextHigh
3.733.733.73
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.592.592.59
Details

Medigene After-Hype Price Prediction Density Analysis

As far as predicting the price of Medigene at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Medigene or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Medigene, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Medigene Estimiated After-Hype Price Volatility

In the context of predicting Medigene's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Medigene's historical news coverage. Medigene's after-hype downside and upside margins for the prediction period are 2.59 and 2.59, respectively. We have considered Medigene's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
2.59
2.59
After-hype Price
2.59
Upside
Medigene is very steady at this time. Analysis and calculation of next after-hype price of Medigene AG is based on 3 months time horizon.

Medigene Pink Sheet Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Medigene is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Medigene backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Medigene, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
 0.00  
0.00
 0.00  
 0.00  
0 Events / Month
2 Events / Month
Uncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
2.59
2.59
0.00 
0.00  
Notes

Medigene Hype Timeline

Medigene AG is now traded for 2.59. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Medigene is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at 0.0%. %. The volatility of related hype on Medigene is about 0.0%, with the expected price after the next announcement by competition of 2.59. The company has price-to-book ratio of 0.92. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medigene AG had not issued any dividends in recent years. Assuming the 90 days horizon the next forecasted press release will be uncertain.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Medigene Related Hype Analysis

Having access to credible news sources related to Medigene's direct competition is more important than ever and may enhance your ability to predict Medigene's future price movements. Getting to know how Medigene's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Medigene may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
GMDAGamida Cell 0.00 0 per month 0.00 (0.05) 6.81 (7.28) 28.30 
NWBONorthwest Biotherapeutics 0.00 0 per month 0.00 (0.08) 6.45 (3.85) 22.79 
CTICCTi Biopharma Corp 0.02 8 per month 0.91  0.13  5.30 (3.58) 85.60 
GERNGeron 0.04 10 per month 0.00 (0.09) 4.17 (4.13) 14.00 
APTCFAdvanced Proteome Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
OXBOFOxford BioDynamics Plc 0.00 0 per month 0.00 (0.18) 0.00  0.00  66.38 
GTHRGeneThera 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
QRONQrons Inc 0.00 0 per month 0.00 (0.19) 0.00  0.00  15.79 
CRPOFCeapro Inc 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
OTLCOncotelic Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
PHASQPhaseBio Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
PCSAProcessa Pharmaceuticals 0.03 3 per month 0.00 (0.16) 6.20 (5.34) 20.99 
KLDOKaleido Biosciences 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 

Medigene Additional Predictive Modules

Most predictive techniques to examine Medigene price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Medigene using various technical indicators. When you analyze Medigene charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Medigene Predictive Indicators

The successful prediction of Medigene stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Medigene AG, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Medigene based on analysis of Medigene hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Medigene's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Medigene's related companies.

Story Coverage note for Medigene

The number of cover stories for Medigene depends on current market conditions and Medigene's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Medigene is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Medigene's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Medigene Short Properties

Medigene's future price predictability will typically decrease when Medigene's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Medigene AG often depends not only on the future outlook of the potential Medigene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Medigene's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding24.6 M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Consideration for investing in Medigene Pink Sheet

If you are still planning to invest in Medigene AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigene's history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital